Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell division cycle associated protein 4 is a nuclear protein that regulates cell cycle progression, mitotic spindle organization, and E2F-dependent transcription, impacting cellular proliferation and apoptosis[1][2][3]. It participates in chromosome segregation and may function as a midzone factor in mitosis[3]. CDCA4 is abnormally expressed in several cancers, including Wilms tumor, breast cancer, and ovarian cancer, where it drives tumor growth by activating the AKT/mTOR pathway and promoting cell proliferation, while inhibiting apoptosis[2][3]. Knockdown of CDCA4 reduces proliferation and increases apoptosis, suggesting its importance as a candidate therapeutic target and biomarker[2].
Experimental: Inhibition of CDCA4 suppresses cell proliferation and promotes apoptosis by downregulating AKT/mTOR signaling. Downregulation affects cyclin D1, AKT, mTOR direct phosphorylation status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell division cycle associated protein 4 (CDCA4).